Expectation of new drugs and new markers against drug resistance Over the years, in the field of breast cancer treatment, targeted drugs and endocrine drug therapy have made rapid progress. At present, I believe that the development of chemotherapy drugs has basically reached a bottleneck. Clinically, in addition to resistance to chemotherapy drugs, there are also resistance to endocrine therapy and resistance to targeted drug therapy. There is also a specific type of breast cancer, triple negative breast cancer, which also accounts for a significant proportion of cases and lacks effective and better treatment drugs and tools other than chemotherapy drugs. Younger patients in this type have poor prognosis and rapid progression. For this group, it is hoped that new targeted or new chemotherapeutic agents will be discovered. For triple negative breast cancer, although there are some drugs, such as PARP inhibitors, with more satisfactory phase 2 clinical results, the phase 3 results are less satisfactory. Triple negative breast cancer is also a complex group, and different staging of triple negative breast cancer has different prognosis. For different types of triple negative breast cancer, if there are some markers to detect and then treat them separately, there will be a greater change for this group in terms of diagnosis, treatment and prognosis. Insights from the research report on the current status of breast cancer treatment in China It should be said that the sample size of this research report led by Professor Jiang and others is very large, and at present, it is the largest sample size of X-Base regimen as a whole management concept at home and abroad. It provides a large sample of data for the subsequent X-maintenance treatment and brings a lot of lessons to clinical practice. The first information is that X-Base combination therapy, either XT with docetaxel or XN with vincristine, is an effective combination therapy with few side effects in the advanced first-line stage. Follow-up X maintenance therapy brings longer PFS to this group of advanced breast cancer patients. The second information is that we did not know about XN combination before, there are only some small sample trials abroad, and before that, we did not have much sample size to have stronger data to support the application of XN regimen in MBC. The poster study led by Prof. Binghe Xu reported at ASCO 2014 and the data of 1200 cases presented by Prof. Jiang at CSCO 2014 gave us an updated guidance for clinical practice. So I think the report is exciting and gives a very good impetus to the treatment of advanced breast cancer in China. The concept of total management throughout the treatment A few days ago, I read an overseas report that proposed the concept of total management for patients with advanced metastatic breast cancer. Professor Jiang raised this concept to a higher level. Professor Jiang suggested that not only the whole process of management and personalized treatment should be implemented for advanced breast cancer, but also the whole process of management for early breast cancer, including early diagnosis, preoperative neoadjuvant treatment, postoperative adjuvant treatment and late palliative treatment. In other words, we adopt a multidisciplinary model and tailor-made approach to effectively manage and treat this group of patients. A management model that involves the patient, the patient’s family, the physician, and the entire community. Using this approach to the treatment of breast cancer patients is a better management model, both in terms of efficacy and in terms of monitoring the whole process.